Skip to main content Skip to navigation
Musculoskeletal Research Group is within the School of Translational Medicine
Musculoskeletal Research Group

BSRBR: publications

  • 2012

    Journal article

    • Mercer, L., Green, A., Galloway, J., Davies, R., Lunt, M., Dixon, W., Watson, K., BSRBR_Control_Centre_Consortium, B., Symmons, D., Hyrich, K. & BSR_Biologics_Register, B (2012). The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, [Epub ahead of print], eScholarID:152345 | PMID:22241900 | DOI:10.1136/annrheumdis-2011-200622

  • 2011

    Journal article

    • Davies, R., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K., BSRBR_Control_Centre_Consortium, B. & BSR_Biologics_Register, B (2011). Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 70(10), 1831-4. eScholarID:130278 | PMID:21784722 | DOI:10.1136/ard.2011.153536
    • Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. (2011). The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 50(7), 1341-1342. eScholarID:154694
    • Galloway, J., Hyrich, K., Mercer, L., Dixon, W., Fu, B., Ustianowski, A., Watson, K., Lunt, M., BSR_Control_Centre_Consortium, B., Symmons, D. & BSR_Biologics_Register, B (2011). Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford), 50(1), 124-131. eScholarID:87498 | PMID:20675706 | DOI:10.1093/rheumatology/keq242
    • Galloway, J., Hyrich, K., Mercer, L., Dixon, W., Ustianowski, A., Helbert, M., Watson, K., Lunt, M., Symmons, D. & BSR_Biologics_Register, B (2011). Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 70(10), 1810-1814. eScholarID:130279 | PMID:21784730 | DOI:10.1136/ard.2011.152769
    • Hyrich, K., Watson, K., Lunt, M., Symmons, D. & BSR_Biologics_Register, B (2011). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford), 50(1), 117-123. eScholarID:88639 | PMID:20671021 | DOI:10.1093/rheumatology/keq209
    • Soliman, M., Ashcroft, D., Watson, K., Lunt, M., Symmons, D., Hyrich, K. & B_S_R_Biologics_Register, B (2011). Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 70(4), 583-589. eScholarID:119065 | PMID:21330639 | DOI:10.1136/ard.2010.139774
    • Strangfeld, A., Hyrich, K., Askling, J., Arkema, E., Davies, R., Listing, J., Neovius, M., Simard, J., Symmons, D., Watson, K. & Zink, A (2011). Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology (Oxford), 50(1), 146-151. eScholarID:92330 | PMID:20861148 | DOI:10.1093/rheumatology/keq301
    • Verstappen, S., King, Y., Watson, K., Symmons, D. & Hyrich, K (2011). Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 70(5), 823-826. eScholarID:120026 | PMID:21362710 | DOI:10.1136/ard.2010.140822

  • 2010

    Journal article

    • Dixon, W., Hyrich, K., Watson, K., Lunt, M., BSRBR_Control_Centre_Consortium, B. & Symmons, D (2010). Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 69(6), 1086-1091. eScholarID:80556 | PMID:20444754 | DOI:10.1136/ard.2009.120626
    • Dixon, W., Hyrich, K., Watson, K., Lunt, M., Galloway, J., Ustianowski, A., BSR_Control_Centre_Consortium, B. & Symmons, D (2010). Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis, 69(3), 522-528. eScholarID:75673 | PMID:19854715 | DOI:10.1136/ard.2009.118935
    • Dixon, W., Watson, K., Lunt, M., Mercer, L., Hyrich, K., Symmons, D. & BSRBR_Control_Centre_Consortium, B (2010). Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken), 62(6), 755-63. eScholarID:82894 | PMID:20535785 | DOI:10.1002/acr.20129
    • Lord, P., Farragher, T., Lunt, M., Watson, K., Symmons, D., Hyrich, K. & BSRBR, B (2010). Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 49(3), 563-567. eScholarID:76173 | PMID:20032223 | DOI:10.1093/rheumatology/kep422
    • Lunt, M., Watson, K., Dixon, W., Symmons, D., Hyrich, K., BSR_Control_Centre_Consortium, B. & BSR_Biologics_Register, B (2010). No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 62(11), 3145-3153. eScholarID:87500 | PMID:20662063 | DOI:10.1002/art.27660
    • Saad, A., Ashcroft, D., Watson, K., Symmons, D., Noyce, P. & Hyrich, K (2010). Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 49(4), 697-705. eScholarID:76328 | PMID:20056769 | DOI:10.1093/rheumatology/kep423
    • Saad, A., Ashcroft, D., Watson, K., Symmons, D., Noyce, P. & Hyrich, K (2010). Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken), 62(3), 345-53. eScholarID:79222 | PMID:20391480 | DOI:10.1002/acr.20104
    • Verstappen, S., Watson, K., Lunt, M., McGrother, K., Symmons, D., Hyrich, K. & BSR_Biologics_Register, B (2010). Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 49(8), 1570-1577. eScholarID:80555 | PMID:20444856 | DOI:10.1093/rheumatology/keq131

  • 2009

    Journal article

    • Harrison MJ, Dixon WG, Watson KD, King YE, Groves R, Hyrich KL, Symmons D, BSRBR Control Centre Consortium. (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 68(2), 209-215. eScholarID:1d17129 | DOI:10.1136/ard.2007.087288
    • Harrison, M., Davies, L., Bansback, N., McCoy, M., Verstappen, S., Watson, K. & Symmons, D (2009). The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res, 18(9), 1195-1205. eScholarID:75064 | PMID:19777373 | DOI:10.1007/s11136-009-9539-2
    • Hyrich, K., Deighton, C., Watson, K., Symmons, D., Lunt, M. & BSRBR_Control_Centre_Consortium, B (2009). Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford), 48(10), 1323-7. eScholarID:75066 | PMID:19706737 | DOI:10.1093/rheumatology/kep242
    • Lunt M, Solomon D, Rothman K, Glynn R, Hyrich KL, Symmons D, Stürmer T. (2009). Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. Am J Epidemiol, 169, (7), 909 - 917. eScholarID:1d18423 | DOI:10.1093/aje/kwn391
    • Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM. (2009). Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther, 11(2), R52. eScholarID:1d19086 | DOI:10.1186/ar2670

  • 2008

    Journal article

    • Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons D. (2008). Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford), 47( 7), 1000-5. eScholarID:1d17516

  • 2007

    Journal article

    • Brennan A, Bansback N, Nixon R, Madan J, Harrison MJ, Watson KD, Symmons D. (2007). Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford), 46( 8), 1345-54. eScholarID:1d16569
    • Dixon WG, Symmons D, Lunt M, Watson KD, Hyrich KL, Silman AJ. (2007). Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum, 56( 9), 2896-904. eScholarID:1d16552
    • Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons D. (2007). Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 56( 9), 2905-12. eScholarID:1d16550
    • Hyrich KL, Lunt M, Watson KD, Symmons D, Silman AJ. (2007). Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum, 56( 1), 13-20. eScholarID:1d15592 | DOI:10.1002/art.22331

  • 2006

    Journal article

    • Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons D. (2006). Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 54, 8, 2368-2376. eScholarID:1d14255 | DOI:10.1002/art.21978
    • Hyrich KL, Symmons D, Watson KD, Silman AJ, BSRBR Control Centre Consortium. (2006). Baseline Comorbidity Levels in Biologic and Standard DMARD Treated Patients with Rheumatoid Arthritis: Results from a National Patient Register. Annals of the Rheumatic Diseases, 65, 7, 895-898. eScholarID:1d14270
    • Hyrich KL, Symmons D, Watson KD, Silman AJ. (2006). Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 54, 6, 1786-1794. eScholarID:1d14260
    • Hyrich KL, Symmons D, Watson KD, Silman AJ. (2006). Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register. Arthritis and Rheumatism, 54, 8, 2701-2702. eScholarID:1d14261
    • Hyrich KL, Watson KD, Silman AJ, Symmons D. (2006). Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 45, 12, 1558-1565. eScholarID:1d14251

  • 2005

    Journal article

    • Hyrich KL, Symmons D, Silman AJ. (2005). Reconciling subject differences in recruitment to clinical trials and clinical practice. J Rheumatol, 32( 12), 2475-6. eScholarID:1d15736
    • Watson, K., Symmons, D., Griffiths, I. & Silman, A (2005). The British Society for Rheumatology biologics register. Ann Rheum Dis, 64 Suppl 4, iv42-3. eScholarID:82705 | PMID:16239385 | DOI:10.1136/ard.2005.042499

  • 2004

    Journal article

    • Hyrich, K., Silman, A., Watson, K. & Symmons, D (2004). Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis, 63(12), 1538-43. eScholarID:82706 | PMID:15242866 | DOI:10.1136/ard.2004.024737

  • 2003

    Journal article

    • Silman AJ, Symmons D, Scott D, Griffiths I. (2003). British Society for Rheumatology Biologics Register. Ann Rheum Dis, 62 Suppl 2, ii28-9. eScholarID:1d8182
    • Silman, A., Symmons, D., Scott, D. & Griffiths, I (2003). British Society for Rheumatology Biologics Register. Ann Rheum Dis, 62 Suppl 2, ii28-9. eScholarID:76536 | PMID:14532144
| Skip to main content | Skip to navigation |